LUNAR Trial Update: ¹⁷⁷Lu-PNT2002 Before SBRT in Oligorecurrent Prostate Cancer
Beyond MSI Status: A New Biomarker of Immunotherapy Resistance in Colorectal Cancer
Zainab Shinkafi-Bagudu Outlines Priorities for the Future of Global Cancer Control - UICC
Enrique Grande: New Review Highlights Major Advances in Perioperative Treatment for Bladder Cancer
City of Hope Receives $11 Million Gift to Advance Personalized Cancer Care
Neoadjuvant vs Definitive ChemoRT in cN3M0 Esophageal Cancer: A Nationwide Dutch Study
Pelé’s Cause of Death: Brazilian Football King’s Battle With Colon Cancer
CT, MRI, and PET/CT in Cancer Diagnosis: Key Differences
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
